Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial

References

• Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US DHHS; 2012. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadoles centgl.pdf (accessed 2012).
   Google Scholar
• Hicks C, King MS, Gulick RM, White AC Jr, Eron JJ Jr, Kessler HA, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS 2004;18:775–9.
   PubMed Web of Science ®Google Scholar
• Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissy JF, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36:1011–9.
   PubMed Web of Science ®Google Scholar
• Sandstrom E, Uhnoo I, Ahlqvist-Rastad J, Bratt G, Berglund T, Gisslen M, et al. Antiretroviral treatment of human immunodeficiency virus infection: Swedish recommendations. Scand J Infect Dis 2003;35:155–67.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva, Switzerland: WHO; 2006.
   Google Scholar
• Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG).AIDS Care 2000;12:255–66.
   PubMed Web of Science ®Google Scholar
• Eden A, Andersson LM, Andersson O, Flamholc L, Josephson F, Nilsson S, et al. Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naive HIV-1-infected patients. AIDS Res Hum Retroviruses 2010;26:533–40.
   PubMed Web of Science ®Google Scholar
• Sierra-Madero J, Villasis-Keever A, Mendez P, Mosqueda-Gomez JL, Torres-Escobar I, Gutierrez-Escolano F, et al. Prospective, randomized, open label trial of efavirenz vs lopinavir/ritonavir in HIV+ treatment-naive subjects with CD4+ < 200 cell/mm3 in Mexico. J Acquir Immune Defic Syndr 2010;53:582–8.
   PubMed Web of Science ®Google Scholar
• Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Van de Casteele T, et al. ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-nai ve HIV-1-infected adults. J Int AIDS Soc 2010;13:P3.
   PubMedGoogle Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010;53:323–32.
   PubMed Web of Science ®Google Scholar
• Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011;154:445–56.
   PubMed Web of Science ®Google Scholar
• Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005;293:817–29.
   PubMed Web of Science ®Google Scholar
• Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009;23:1679–88.
   PubMed Web of Science ®Google Scholar
• Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011; 204:1191–201.
   PubMed Web of Science ®Google Scholar
• Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251–60.
   PubMed Web of Science ®Google Scholar
• Cooper V, Moyle GJ, Fisher M, Reilly G, Ewan J, Liu HC, et al. Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz. AIDS Care 2011; 23:705–13.
   PubMed Web of Science ®Google Scholar
• Maljkovic I, Wilbe K, Solver E, Alaeus A, Leitner T. Limited transmission of drug-resistant HIV type 1 in 100 Swedish newly detected and drug-naive patients infected with subtypes A, B, C, D, G, U, and CRF01_AE. AIDS Res Hum Retroviruses 2003;19:989–97.
   PubMed Web of Science ®Google Scholar
• Karlsson A, Bjorkman P, Bratt G, Ekvall H, Gisslen M, Sonnerborg A, et al. Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003–2010. PLoS One 2012;7:e33484.
   PubMed Web of Science ®Google Scholar
• Frentz D, Boucher CA, van de Vijver DA. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev 2012;14:17–27.
   PubMed Web of Science ®Google Scholar